News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Total transaction value of the divestment is Rs. 3,660 million
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Subscribe To Our Newsletter & Stay Updated
